CN116348132A - 基于合成的被修饰的痘苗安卡拉（smva）的冠状病毒疫苗 - Google Patents

基于合成的被修饰的痘苗安卡拉（smva）的冠状病毒疫苗 Download PDF

Info

Publication number
CN116348132A
CN116348132A CN202180059838.6A CN202180059838A CN116348132A CN 116348132 A CN116348132 A CN 116348132A CN 202180059838 A CN202180059838 A CN 202180059838A CN 116348132 A CN116348132 A CN 116348132A
Authority
CN
China
Prior art keywords
smva
protein
antigen
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180059838.6A
Other languages
English (en)
Chinese (zh)
Inventor
唐·J·戴蒙德
费利克斯·乌索
弗拉维亚·奇乌佩西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of CN116348132A publication Critical patent/CN116348132A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180059838.6A 2020-05-17 2021-05-17 基于合成的被修饰的痘苗安卡拉（smva）的冠状病毒疫苗 Pending CN116348132A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063026127P 2020-05-17 2020-05-17
US63/026,127 2020-05-17
US202063044033P 2020-06-25 2020-06-25
US63/044,033 2020-06-25
US202063113810P 2020-11-13 2020-11-13
US63/113,810 2020-11-13
US202163161371P 2021-03-15 2021-03-15
US63/161,371 2021-03-15
PCT/US2021/032821 WO2021236550A1 (en) 2020-05-17 2021-05-17 Synthetic modified vaccinia ankara (smva) based coronavirus vaccines

Publications (1)

Publication Number Publication Date
CN116348132A true CN116348132A (zh) 2023-06-27

Family

ID=78708032

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059838.6A Pending CN116348132A (zh) 2020-05-17 2021-05-17 基于合成的被修饰的痘苗安卡拉（smva）的冠状病毒疫苗

Country Status (11)

Country Link
US (2) US20230323389A1 (https=)
EP (1) EP4153228A4 (https=)
JP (2) JP7788403B2 (https=)
KR (1) KR20230012583A (https=)
CN (1) CN116348132A (https=)
AU (1) AU2021276265A1 (https=)
BR (1) BR112022023173A2 (https=)
CA (1) CA3183016A1 (https=)
IL (1) IL298210A (https=)
MX (1) MX2022014387A (https=)
WO (1) WO2021236550A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
WO2023056284A1 (en) * 2021-09-29 2023-04-06 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronavirus infection
WO2023092021A1 (en) * 2021-11-17 2023-05-25 City Of Hope Synthetic modified vaccinia ankara (smva) based coronavirus vaccines
EP4558171A1 (en) * 2022-07-22 2025-05-28 City of Hope Synthetic modified vaccinia ankara vaccines to stimulate orthopox and monkeypox virus immunity
EP4316514A1 (en) * 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2
TW202426045A (zh) * 2022-10-07 2024-07-01 高端疫苗生物製劑股份有限公司 抗新型冠狀病毒(SARS-CoV-2) Omicron變異株之免疫組合物
WO2026030724A1 (en) * 2024-08-01 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071250A2 (en) * 2004-04-05 2006-07-06 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Soluble fragments of the sars-cov spike glycoprotein
WO2016116398A1 (en) * 2015-01-19 2016-07-28 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (mers-cov)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus
EP2363493B1 (en) 2003-02-20 2012-11-14 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
US20070092936A1 (en) * 2003-05-08 2007-04-26 Haynes Barton F Severe acute respiratory syndrome
WO2005028634A2 (en) * 2003-09-18 2005-03-31 Emory University Improved mva vaccines
DK2062023T4 (en) 2006-08-25 2017-02-20 The Government Of The Us Secretary Dept Of Health And Human Services INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS
DK2488649T3 (da) 2009-10-16 2019-06-17 Us Health Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder
US20210260181A1 (en) * 2014-09-16 2021-08-26 Altimmune, Inc Coronavirus immunogenic compositions and uses thereof
WO2017209053A1 (ja) 2016-05-30 2017-12-07 アステラス製薬株式会社 新規な遺伝子組換えワクシニアウイルス
JP2019535311A (ja) 2016-11-02 2019-12-12 デイビッド エバンス， 合成キメラポックスウイルス
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
WO2019014569A1 (en) * 2017-07-13 2019-01-17 City Of Hope EXPRESSION SYSTEM FOR EXPRESSING GLYCOPROTEIN COMPLEXES OF HERPESVIRUS
EP3788142A4 (en) * 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS
JP2023512519A (ja) 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
CA3168836A1 (en) 2020-02-03 2021-08-12 City Of Hope Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
KR20220144416A (ko) 2020-02-04 2022-10-26 큐어백 아게 코로나바이러스 백신
IL295548A (en) * 2020-02-14 2022-10-01 Altimmune Inc Immunogenic compositions of the corona virus and their uses
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
GB2594683A (en) 2020-02-17 2021-11-10 Vaxbio Ltd Vaccine
KR20220165731A (ko) * 2020-02-26 2022-12-15 토닉스 파마 리미티드 Sars-cov-2 바이러스에 대한 재조합 폭스바이러스 기반 백신
WO2021178416A1 (en) * 2020-03-02 2021-09-10 Heat Biologics, Inc. Immune-mediated coronavirus treatments
US11202753B1 (en) * 2020-03-06 2021-12-21 Aquavit Pharmaceuticals, Inc. Systems and methods for generating immune responses in subjects using microchannel delivery devices
JP2023517286A (ja) 2020-03-13 2023-04-25 オックスフォード ユニヴァーシティ イノヴェーション リミテッド 免疫応答を誘導するための組成物及び方法
US20210299245A1 (en) 2020-03-31 2021-09-30 Sementis Limited Attenuated poxvirus vector based vaccine for protection against covid-19
US20230143228A1 (en) 2020-04-21 2023-05-11 Emory University Coronavirus vaccines, compositions, and methods related thereto
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
US20220370600A1 (en) * 2021-05-21 2022-11-24 Board Of Regents, The University Of Texas System Multigenic mva-sars-cov-2 vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071250A2 (en) * 2004-04-05 2006-07-06 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Soluble fragments of the sars-cov spike glycoprotein
WO2016116398A1 (en) * 2015-01-19 2016-07-28 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (mers-cov)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FLAVIA CHIUPPESI等: "Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform", NATURE COMMUNICATION, vol. 11, 31 December 2020 (2020-12-31), pages 6121 *
MARKUS CZUB等: "Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets", VACCINE, vol. 23, 23 January 2005 (2005-01-23), pages 2273 - 2279 *
WEILONG SHANG等: "The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines", NPJ VACCINE, vol. 5, 6 March 2020 (2020-03-06), pages 1 *
ZHIWEI CHEN等: "Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region", JOURNAL OF VIROLOGY, vol. 79, no. 5, 31 March 2005 (2005-03-31), pages 2678 - 2688 *

Also Published As

Publication number Publication date
BR112022023173A2 (pt) 2022-12-27
US20250313858A1 (en) 2025-10-09
KR20230012583A (ko) 2023-01-26
EP4153228A1 (en) 2023-03-29
CA3183016A1 (en) 2021-11-25
US20230323389A1 (en) 2023-10-12
AU2021276265A1 (en) 2022-12-08
WO2021236550A1 (en) 2021-11-25
MX2022014387A (es) 2023-04-11
EP4153228A4 (en) 2024-07-10
JP2026041921A (ja) 2026-03-10
JP2023526073A (ja) 2023-06-20
US12584146B2 (en) 2026-03-24
JP7788403B2 (ja) 2025-12-18
IL298210A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
US12584146B2 (en) Synthetic modified vaccinia Ankara (SMVA) based coronavirus vaccines
Chiuppesi et al. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform
JP2023513913A (ja) 麻疹ベクターを用いたｃｏｖｉｄ－１９免疫原性組成物及びワクチン
Li et al. Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice
CN115605225A (zh) 用于针对covid-19进行保护的基于减毒痘病毒载体的疫苗
Small et al. Viruses—From pathogens to vaccine carriers
US11844833B2 (en) Expression system for expressing herpesvirus glycoprotein complexes
WO2012053646A1 (ja) ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター
US11253587B2 (en) Vaccine compositions for the treatment of coronavirus
AU2025287330A1 (en) Poxvirus-based vectors produced by natural or synthetic DNA and uses thereof
Guerbois et al. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160ΔV1V2 is strongly immunogenic
Liniger et al. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses
Khattar et al. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector
Chiuppesi et al. Development of a synthetic poxvirus-based SARS-CoV-2 vaccine
JP2023528984A (ja) コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン
US20250215456A1 (en) Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
US20250161435A1 (en) Multivalent kaposi sarcoma-associated herpesvirus-like particles and uses thereof
EP4358999A1 (en) Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein
EP4316514A1 (en) Mva-based vectors and their use as vaccine against sars-cov-2
Rong et al. Antivirals for Emerging Viruses: Vaccines and Therapeutics
Khan Development of immunogenic, distributable, and equitable SARS-CoV-2 vaccines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination